HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on Poseida Therapeutics (NASDAQ:PSTX) and maintains a $20 price target.
July 25, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on Poseida Therapeutics and maintains a $20 price target.
The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100